



## Eldrin F. Lewis, MD, MPH

Simon H Stertzler, M.D. Professor  
Medicine - Cardiovascular Medicine

### CLINICAL OFFICES

300 Pasteur Dr

CVRB MC 5406

Stanford, CA 94305

Tel (650) 724-8773

Fax (650) 725-1599

### Bio

---

#### BIO

Dr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine.

Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.

A fundamental principle of Dr. Lewis' practice is his belief that "there is more to life than death," that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.

Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.

Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people's ability to function and perform their activities of daily living. Strategies to improve patients' well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.

Dr. Lewis' commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford's proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.

He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.

Dr. Lewis' honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.

He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials.

## CLINICAL FOCUS

- Cardiovascular Disease

## ACADEMIC APPOINTMENTS

- Professor - Med Center Line, Medicine - Cardiovascular Medicine

## PROFESSIONAL EDUCATION

- Board Certification: Advanced Heart Failure and Transplant Cardiology, American Board of Internal Medicine (2014)
- Board Certification: Cardiovascular Disease, American Board of Internal Medicine (2003)
- Fellowship: Brigham and Women's Hospital Heart Transplant (2002) MA
- Fellowship: Brigham and Women's Hospital Cardiovascular Disease Fellowship (2001) MA
- Residency: Brigham and Women's Hospital Internal Medicine Residency (1998) MA
- Medical Education: Perelman School of Medicine University of Pennsylvania (1995) PA

## Publications

---

### PUBLICATIONS

- **Cardiovascular Safety and Efficacy of Vadadust for the Treatment of Anemia in Non-Dialysis Dependent CKD: Design and Baseline Characteristics.** *American heart journal*  
Chertow, G. M., Pergola, P. E., Agarwal, R., Block, G. A., Farag, Y. M., Jardine, A. G., Koury, M. J., Luo, W., Khawaja, Z., Lewis, E. F., Matsushita, K., McCullough, P. A., Parfrey, et al  
2020
- **Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial.** *Cardiovascular diabetology*  
Wijkman, M. O., Claggett, B., Diaz, R., Gerstein, H. C., Kober, L., Lewis, E., Maggioni, A. P., Wolsk, E., Aguilar, D., Bentley-Lewis, R., McMurray, J. J., Probstfield, J., Riddle, et al  
2020; 19 (1): 175
- **Associations Between Depressive Symptoms and HFpEF-Related Outcomes.** *JACC. Heart failure*  
Chandra, A., Alcalá, M. A., Claggett, B., Desai, A. S., Fang, J. C., Heitner, J. F., Liu, J., Pitt, B., Solomon, S. D., Pfeffer, M. A., Lewis, E. F.  
2020

- **Response by Eberly et al to Letter Regarding Article, "Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center".** *Circulation. Heart failure*  
Eberly, L. A., Wispelwey, B., Richterman, A., Beckett, A. G., Cleveland Manchanda, E. C., Marsh, R. H., Chang, C. Y., Glynn, R. J., Brooks, K. C., Boxer, R., Kakoza, R., Goldsmith, J., Loscalzo, et al  
2020; CIRCHEARTFAILURE120007193
- **Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel from the Heart Failure Collaboratory and Academic Research Consortium (HF-ARC).** *European journal of heart failure*  
Abraham, W. T., Psotka, M. A., Fiuzat, M., Filippatos, G., Lindenfeld, J., Mehran, R., Ambardekar, A. V., Carson, P. E., Jacob, R., Januzzi, J. L., Konstam, M. A., Krucoff, M. W., Lewis, et al  
2020
- **Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel.** *Journal of the American College of Cardiology*  
Psotka, M. A., Abraham, W. T., Fiuzat, M., Filippatos, G., Lindenfeld, J., Ahmad, T., Bhatt, A. S., Carson, P. E., Cleland, J. G., Felker, G. M., Januzzi, J. L., Kitzman, D. W., Leifer, et al  
2020; 76 (20): 2368–78
- **Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)** *AMERICAN JOURNAL OF KIDNEY DISEASES*  
Mc Causland, F. R., Claggett, B., Burdmann, E. A., Chertow, G. M., Cooper, M. E., Eckardt, K., Ivanovich, P., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. V., Parfrey, P., Parving, et al  
2019; 73 (3): 309–15
- **Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).** *American journal of kidney diseases : the official journal of the National Kidney Foundation*  
Mc Causland, F. R., Claggett, B., Burdmann, E. A., Chertow, G. M., Cooper, M. E., Eckardt, K., Ivanovich, P., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J., Parfrey, P., Parving, et al  
2018
- **2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*  
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., Morrow, D. A., Targum, S. L., Sila, et al  
2018; 71 (9): 1021–34
- **2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials** *CIRCULATION*  
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Mar-Ler, J. R., Teerlink, J. R., Farb, A., Morrow, D. A., Targum, S. L., Sila, et al  
2018; 137 (9): 961–72